Latest Gynecologic oncology Stories
HUNTSVILLE, Ala., Dec. 13, 2010 /PRNewswire/ -- EGEN, Inc. today announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment.
QUEBEC, Dec. 7 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS,TSX:Â AEZ) (the "Company") will hold an R&D Review for investors and analysts on Tuesday, December 14, 2010 from 4 p.m. to 6 p.m.
CALGARY, Dec. 1 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the start of enrollment in a randomized Phase II ovarian cancer study.
New wordoncancer.org Website Launched To Spread Awareness about Gynecologic Cancers by Womenâ€™s Oncology Research & Dialogue (WORD) Women's Oncology Research & Dialogue has lanched a new website to inform women about ovarian, uterine, cervical and all gynecologic cancers at wordoncancer.org. Indianapolis, IN (PRWEB) November 9, 2010 On November 9, 2010 Womenâ€™s Oncology Research & Dialogue launched their new website at http://www.wordoncancer.org. WORD was founded...
AUSTIN, Texas, Oct.
An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.
Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology  today (Wednesday 29 September).
VANCOUVER, Sept. 8 /PRNewswire/ - Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A.
PRESENTS "SCOPE OF EXCELLENCE" AWARDS Writer and Performer, Jenny Allen Will Emcee Brunch MORRISTOWN, N.J., Sept.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.